SCHEMBL647325

SCHEMBL647325

CN1C(=O)CC[C@H]1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ACE P12821 2/20 0.47
P2RX7 Q99572 18/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1850331 1.00 ACE (0.47) ACEP2RX7
SCHEMBL1587617 1.00 ACE (0.47) ACEP2RX7
SCHEMBL159149 1.00 ACE (0.47) ACEP2RX7
Ammonia Solution, Strong SCHEMBL11295703 0.98 ACE (0.46) ACEP2RX7
SCHEMBL16339447 0.88 P2RX7 (0.44) ACEP2RX7
SCHEMBL30813130 0.88 P2RX7 (0.44) ACEP2RX7
SCHEMBL16339048 0.88 P2RX7 (0.44) ACEP2RX7
SCHEMBL18212792 0.86 ACE (0.44) ACEP2RX7
SCHEMBL13949148 0.83 P2RX7 (0.45) P2RX7
SCHEMBL18101128 0.83 P2RX7 (0.45) P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3967714-B1 VINYL ALCOHOL-AMINO ACID ESTER COPOLYMER, THEIR PREPARATION AND USES SEKISUI CHEMICAL CO LTD (JP) 2026-01-07 EP claimed
WO-2022221942-A1 PREVENTION OF DRUG DIVERSION BETTERLIFE PHARMA INC. (CA) 2022-10-27 WO claimed
EP-2670722-B1 CHIRAL 1-(4-METHYLPHENYLMETHYL)-5-OXO-{N-[(3-T-BUTOXYCARBONYL-AMINOMETHYL)]-PIPERIDIN-1-YL}-PYRROLIDINE-2-CARBOXAMIDES AS INHIBITORS OF COLLAGEN INDUCED PLATELET ACTIVATION AND ADHESION COUNCIL SCIENT IND RES (IN) 2016-10-12 EP claimed
US-20130338193-A1 CHIRAL 1-(4-METHYLPHENYLMETHYL)-5-OXO--PYRROLIDINE-2-CARBOXAMIDES AS INHIBITORS OF COLLAGEN INDUCED PLATELET ACTIVATION AND ADHESION COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-12-19 US claimed
US-20100163070-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBRES USING HEATING MEANS AND AN AMIDE L'OREAL S.A. (FR) 2010-07-01 US claimed
WO-2005094854-A1 MODIFIED NUTRACEUTICAL COMPOSITION TORBANGUN PTY LTD (AU) 2005-10-13 WO claimed
EP-0594608-B1 CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS RES CORP TECHNOLOGIES INC (US) 1997-10-15 EP claimed
EP-3985001-B1 PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER SERVIER LAB (FR) 2026-04-29 EP disclosed
EP-4631573-A2 TEAD INHIBITORS Orion Corporation (FI) 2025-10-15 EP disclosed
EP-4323338-B1 TEAD INHIBITORS ORION CORP (FI) 2025-10-08 EP disclosed
WO-2025133105-A1 COMPOSITIONS AND METHODS BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) 2025-06-26 WO disclosed
US-20250177354-A1 THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES MINDSTATE DESIGN LABS INC (US) 2025-06-05 US disclosed
US-20250100997-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2025-03-27 US disclosed
EP-0210065-A1 6-Alkylidene penems BEECHAM GROUP PLC (GB) 1987-01-28 EP disclosed
EP-0015771-B1 N-(6-((ACYLAMINOACYLAMINO OR AMINOACYLAMINO)PHENYL)-1,2-DIHYDRO-2-OXONICOTINYL) CEPHALOSPORIN COMPOUNDS, PROCESSES FOR THEIR PRODUCTION, AND COMPOSITIONS CONTAINING THE SAME WARNER-LAMBERT COMPANY (US) 1984-06-06 EP disclosed
EP-0015773-B1 N-(6-((ACYLAMINOACYLAMINO OR AMINOACYLAMINO)PHENYL) 1,2-DIHYDRO-2-OXONICOTINYL)PENICILLIN COMPOUNDS, PROCESSES FOR THEIR PRODUCTION AND COMPOSITIONS CONTAINING THEM WARNER-LAMBERT COMPANY (US) 1983-07-20 EP disclosed
US-4311698-A Aminoacid derivatives of cephalosporin compounds HASKELL THEODORE H 1982-01-19 US disclosed
US-4278681-A N-/6-//ACYLAMINOACYLAMINO OR AMINOACYLAMINO/PHENYL/-1,2-DIHYDRO-2-OXONICOTINYL/PENICILLINS WARNER-LAMBERT CO. (US) 1981-07-14 US disclosed
EP-0015773-A2 N-(6-((acylaminoacylamino or aminoacylamino)phenyl) 1,2-dihydro-2-oxonicotinyl)penicillin compounds, processes for their production and compositions containing them WARNER-LAMBERT COMPANY (US) 1980-09-17 EP disclosed
EP-0015771-A1 N-(6-((acylaminoacylamino or aminoacylamino)phenyl)-1,2-dihydro-2-oxonicotinyl) cephalosporin compounds, processes for their production, and compositions containing the same WARNER-LAMBERT COMPANY (US) 1980-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250177354-A1 THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES CNR2, CNR1, HTR6 ACE 2541/4885P2RX7 126/4885
US-20130338193-A1 CHIRAL 1-(4-METHYLPHENYLMETHYL)-5-OXO--PYRROLIDINE-2-CARBOXAMIDES AS INHIBITORS OF COLLAGEN INDUCED PLATELET ACTIVATION AND ADHESION PLOD1, PLOD3, PLOD2 ACE 3663/4885P2RX7 628/4885
US-20250100997-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS ALK, TGFBR1, ACVR1 ACE 926/4885P2RX7 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.